Prevention of Stroke in Patients With Systemic Lupus Erythematosus

To the Editor:

In the paper by Futrell and Millikan, the authors recommend anticoagulant therapy as the most effective preventive treatment for patients with systemic lupus erythematosus (SLE) who have had a stroke, transient ischemic attack, or cardiac valvular disease. They postulate that since cardiac emboli are the cause of strokes in SLE patients, they are best prevented by anticoagulants. They also evaluated lupus anticoagulant in only eight of 13 patients with SLE and stroke, since patients with lupus anticoagulant in systemic lupus erythematosus. Ann Intern Med 1979; 22:313–320.

Recently, Briley and colleagues reported 25 patients with elevated anticardiolipin antibody levels and associated neurological symptoms, 15 of them with SLE or a lupus-like syndrome and eight with positive lupus anticoagulant. They speculated that cross-reactivity anticardiolipin antibody or lupus anticoagulant with platelets or endothelium might be responsible for thrombosis. Although they did not find a consistent trend in their various treatment results, including anticoagulants, they emphasize that three patients who received plasmapheresis and immunosuppressive therapy appeared to respond in temporal relation to the therapy.

Futrell and Millikan treated with anticoagulants only seven patients with SLE and transient ischemic attacks or stroke, and one only of these revealed that the source of stroke was cardiac. They also evaluated lupus anticoagulant in only eight of 13 patients with SLE and stroke. Based on these findings, we consider their recommendation to treat with anticoagulants the SLE patients who have had a stroke, transient ischemic attack, or cardiac valvular disease not entirely valid. Moreover, since anticoagulant therapy does not correct the fibrinolytic defect in SLE, we suggest evaluating both anticardiolipin antibodies and lupus anticoagulant therapy in patients with SLE and stroke, since patients with anticardiolipin antibody may not exhibit lupus anticoagulant. We also recommend considering immunosuppressive therapy in these patients.

A. Achiron
Department of Neurology
Beilinson Medical Center
Petah Tiqwa, Israel

I. Sarova-Pinhas
Department of Neurology
Wolfson Medical Center
Holon, Israel

References


The following is in response:

To the Editor:

Stroke is only one of many types of neurological disease in patients with systemic lupus erythematosus (SLE), and combining all of them into “central nervous system lupus” as do Achiron and Savova-Pinhas is misleading. The need for careful classification of the types of nervous system involvement in SLE is being increasingly recognized.

The references used by Achiron and Savova-Pinhas do not support their hypothesis that the deposition of immune complexes in the choroid produces nervous system pathology. Atkins et al specifically state that this immune complex deposition was seen in all patients with SLE, whether or not they had nervous system involvement. They concluded that these deposits are not specific for nervous system involvement in SLE and also suggest that circulating antibodies to neuronal elements may cause “cerebral lupus.” Although Bluestein et al postulate that anti-neuronal antibodies may cause some types of nervous system disease, they conclude that focal cerebral ischemia is caused by focal pathology in cerebral vessels. The use of immunosuppressant medication in the study of Briley et al cannot be applied to our patients since they were treating patients with diffuse encephalopathy rather than patients with focal cerebral ischemia or infarction. It is also not known how many patients in their study actually had SLE.

Our hypothesis that the major cause of stroke in SLE is from cardiogenic emboli is based on the frequent valvar disease in our patients and is supported by a major autopsy study. Achiron and Savova-Pinhas consider our suggestion that anticoagulants be used to prevent stroke in SLE invalid because only seven patients were treated with anticoagulants. The suggestion to anticoagulate patients with SLE following a stroke or a transient ischemic attack was not based solely on these patients, but also on 1) three studies in the literature suggesting that anticoagulant seemed effective in preventing stroke, 2) reports that anticoagulant is the treatment of choice for the prevention of systemic thrombosis in patients with SLE, 3) the autopsy documentation of cardiogenic embolus as a major cause of stroke in SLE, and 4) the need to correct the balance between fibrin formation and lysis. Achiron and Savova-Pinhas incorrectly state that “eight of the 13 stroke patients” were tested for lupus anticoagulant. Our Table 2 (Reference 5) shows that 10 of the 14 group A stroke patients were tested for lupus anticoagulant. The other four stroke patients were studied retrospectively and could not be tested for lupus anticoagulant. Of the 10 stroke patients who were tested, only four had lupus anticoagulant. Thus, lupus anticoagulant testing alone fails to predict stroke risk in SLE.

We agree that anticardiolipin antibody and lupus anticoagulant should be evaluated in all stroke patients with SLE, but the partial retrospective nature of our study and the fact that anticardiolipin antibody assays were not available at the time of the stroke in most of our patients made this impossible. It is important to point out that the role of lupus anticoagulant or anticardiolipin antibody in the production of thrombosis in patients with SLE has not been determined, and Laskin and Solonika state that the predictive...
value of the anticardiolipin antibody is too questionable to be a criterion upon which to base any therapeutic decision. Meyer et al.13 compared anticardiolipin subtypes in patients with SLE and syphilis and concluded that IgG anticardiolipin may be an epiphenomenon and is probably not implicated in the pathogenesis of the thrombotic diathesis seen in SLE. This controversial area has not yet been adequately studied. The suggestion of Achiron and Sarova-Pinhas that these patients be treated with immunosuppression is startling in view of the serious complications of immunosuppression and the absence of evidence that such therapy would reduce the risk of cardiogenic emboli in patients with SLE.

Nancy Futrell, MD
Clark Millikan, MD
Department of Neurology
Henry Ford Hospital
Detroit, Michigan

References
A Achiron and I Sarova-Pinhas

Stroke. 1990;21:154-155
doi: 10.1161/01.STR.21.1.154
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1990 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/21/1/154.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in
Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office.
Once the online version of the published article for which permission is being requested is located, click Request
Permissions in the middle column of the Web page under Services. Further information about this process is
available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/